Cogentin and Salivary hypersecretion - a phase IV clinical study of FDA data

Summary:

Salivary hypersecretion is reported as a side effect among people who take Cogentin (benztropine mesylate), especially for people who are female, 60+ old, also take Clozaril, and have High blood pressure.

The phase IV clinical study analyzes which people have Salivary hypersecretion when taking Cogentin. It is created by eHealthMe based on reports of 7,418 people who have side effects when taking Cogentin from the FDA, and is updated regularly.

What is Cogentin?

Cogentin has active ingredients of benztropine mesylate. It is often used in tardive dyskinesia. eHealthMe is studying from 7,692 Cogentin users. Check the latest studies of Cogentin.

What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 779 drugs and 1,338 conditions by eHealthMe. Check the latest studies of Salivary hypersecretion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

7,418 people reported to have side effects when taking Cogentin.
Among them, 54 people (0.73%) have Salivary hypersecretion.

Could Cogentin cause Salivary hypersecretion?

Among these 54 people:

What is the gender of people who have Salivary hypersecretion when taking Cogentin? *

female: 53.06 %
male: 46.94 %

What is the age of people who have Salivary hypersecretion when taking Cogentin? *

What are other drugs people take besides Cogentin? *

What are other side effects people have besides Salivary hypersecretion? *

Fatigue (feeling of tiredness): 7 people, 12.96%
Drowsiness: 7 people, 12.96%
Drug Withdrawal Syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation): 5 people, 9.26%
Swallowing Difficulty: 5 people, 9.26%
Nausea (feeling of having an urge to vomit): 5 people, 9.26%
Hallucination, Auditory (perceiving sounds without auditory stimulus): 5 people, 9.26%
Insomnia (sleeplessness): 5 people, 9.26%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 5 people, 9.26%
Movement - Uncontrolled Or Slow: 4 people, 7.41%
Constipation: 4 people, 7.41%

What are the existing conditions these people have? *

Schizophrenia, Paranoid Type (delusions and auditory hallucinations but relatively normal intellectual functioning and expression of affect): 3 people, 5.56%
Psychotic Disorder: 3 people, 5.56%
Dyslipidaemia (abnormal amount of lipids): 3 people, 5.56%
High Blood Cholesterol: 3 people, 5.56%
High Blood Pressure: 3 people, 5.56%
Nail Disorder (disease of nail): 2 people, 3.70%
Hypersensitivity: 2 people, 3.70%
Rashes (redness): 2 people, 3.70%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 2 people, 3.70%
Depression: 2 people, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Cogentin and have Salivary hypersecretion?

- Check whether Salivary hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cogentin:

Cogentin (7,692 reports)

Browse all side effects of Cogentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Salivary hypersecretion:

Salivary hypersecretion (779 drugs)

Browse all the conditions that are associated with Salivary hypersecretion:

Salivary hypersecretion (1,338 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on benztropine mesylate (the active ingredients of Cogentin) and Cogentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.